Condition
HR+ HER2- Breast Cancer
Total Trials
3
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT07558733Phase 1RecruitingPrimary
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
NCT07029399Phase 1Recruiting
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT06774027Recruiting
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Showing all 3 trials